|
US9045518B2
(en)
|
2002-11-18 |
2015-06-02 |
Santaris Pharma A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
|
EP2379084B1
(en)
|
2008-10-15 |
2017-11-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
|
SG171914A1
(en)
|
2008-12-02 |
2011-07-28 |
Chiralgen Ltd |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
EP2451461A4
(en)
|
2009-07-06 |
2013-05-29 |
Ontorii Inc |
NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
|
|
DK2620428T3
(da)
|
2010-09-24 |
2019-07-01 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
|
WO2012068405A2
(en)
|
2010-11-17 |
2012-05-24 |
Isis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
JP6129844B2
(ja)
|
2011-09-14 |
2017-05-17 |
ラナ セラピューティクス インコーポレイテッド |
多量体オリゴヌクレオチド化合物
|
|
KR20150030205A
(ko)
|
2012-05-16 |
2015-03-19 |
라나 테라퓨틱스, 인크. |
Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
|
|
JP2015523853A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Ａｔｐ２ａ２発現を調節するための組成物及び方法
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
EA201492121A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии семейства генов гемоглобина
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
SG11201407486PA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating utrn expression
|
|
CN112007045B
(zh)
|
2012-07-13 |
2026-01-06 |
波涛生命科学有限公司 |
手性控制
|
|
DK2872485T3
(da)
|
2012-07-13 |
2021-03-08 |
Wave Life Sciences Ltd |
Asymmetrisk hjælpegruppe
|
|
CA2884608C
(en)
|
2012-09-14 |
2025-05-20 |
Translate Bio Ma, Inc. |
MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
|
|
SG10201804331TA
(en)
|
2012-11-15 |
2018-07-30 |
Roche Innovation Ct Copenhagen As |
Oligonucleotide conjugates
|
|
US20150368642A1
(en)
*
|
2013-01-30 |
2015-12-24 |
Hoffmann-La Roche Inc. |
Lna oligonucleotide carbohydrate conjugates
|
|
EP2992095B1
(en)
|
2013-05-01 |
2019-01-09 |
Regulus Therapeutics Inc. |
Microrna compounds and methods for modulating mir-122
|
|
CA2921162A1
(en)
|
2013-05-01 |
2014-11-06 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
CN105164261B
(zh)
|
2013-05-01 |
2022-03-18 |
莱古路斯治疗法股份有限公司 |
用于增强的细胞摄取的化合物和方法
|
|
US9943604B2
(en)
|
2013-09-20 |
2018-04-17 |
Ionis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
EP3060664B1
(en)
|
2013-10-25 |
2021-07-07 |
Sanofi |
Microrna compounds and methods for modulating mir-21 activity
|
|
EP3095461A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
WO2015108048A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
KR102423317B1
(ko)
|
2014-01-16 |
2022-07-22 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
|
JP2017505623A
(ja)
|
2014-01-30 |
2017-02-23 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
生物切断性コンジュゲートを有するポリオリゴマー化合物
|
|
CN116970607A
(zh)
|
2014-03-19 |
2023-10-31 |
Ionis制药公司 |
用于调节共济失调蛋白2表达的组合物
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
MY192634A
(en)
|
2014-04-01 |
2022-08-29 |
Biogen Ma Inc |
Compositions for modulating sod-1 expression
|
|
US10280423B2
(en)
|
2014-05-01 |
2019-05-07 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating complement factor B expression
|
|
AU2015252841B2
(en)
|
2014-05-01 |
2020-03-19 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
|
JP6665111B2
(ja)
|
2014-05-01 |
2020-03-13 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｐｋｋ発現を調節するための組成物及び方法
|
|
MX382230B
(es)
|
2014-05-01 |
2025-03-13 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3.
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
US9487783B2
(en)
*
|
2014-08-07 |
2016-11-08 |
Regulus Therapeutics Inc. |
Targeting microRNAs for metabolic disorders
|
|
WO2016040748A1
(en)
|
2014-09-12 |
2016-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for detection of smn protein in a subject and treatment of a subject
|
|
US20170327524A1
(en)
|
2014-10-10 |
2017-11-16 |
Hoffmann-La Roche, Inc. |
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
|
|
SG11201703646SA
(en)
*
|
2014-11-10 |
2017-06-29 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Combination long acting compositions and methods for hepatitis c
|
|
US10815481B2
(en)
|
2014-12-16 |
2020-10-27 |
Roche Innovation Center Copenhagen A/S |
Chiral library screen
|
|
EP3234141A4
(en)
*
|
2014-12-18 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
WO2016130943A1
(en)
*
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
EP3277815B1
(en)
|
2015-04-03 |
2021-09-22 |
University of Massachusetts |
Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
|
|
JP7009356B2
(ja)
|
2015-04-03 |
2022-01-25 |
ユニバーシティ・オブ・マサチューセッツ |
ハンチンチンｍＲＮＡをターゲティングするオリゴヌクレオチド化合物
|
|
WO2016161388A1
(en)
|
2015-04-03 |
2016-10-06 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
HK1249140A1
(zh)
|
2015-04-03 |
2018-10-26 |
Ionis Pharmaceuticals, Inc. |
用於调节tmprss6表达的化合物和方法
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
WO2017030973A1
(en)
*
|
2015-08-14 |
2017-02-23 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
HK1252479A1
(zh)
|
2015-08-24 |
2019-05-24 |
Roche Innovation Center Copenhagen A/S |
Lna-g方法
|
|
WO2017053995A1
(en)
*
|
2015-09-25 |
2017-03-30 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
JP6893505B2
(ja)
|
2015-10-02 |
2021-06-23 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドコンジュゲーション方法
|
|
EP3359523A4
(en)
|
2015-10-09 |
2019-07-24 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
SI4119569T1
(sl)
*
|
2015-11-06 |
2024-10-30 |
Ionis Pharmaceuticals, Inc. |
Konjugirane protismiselne spojine za uporabo v terapiji
|
|
EP3370708A4
(en)
|
2015-11-06 |
2019-06-26 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF APOLIPOPROTEIN (A) EXPRESSION
|
|
UA125963C2
(uk)
|
2015-11-12 |
2022-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Олігонуклеотид для індукції батьківської експресії ube3a
|
|
US11058709B1
(en)
|
2015-12-04 |
2021-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
CA3006015A1
(en)
|
2015-12-31 |
2017-07-06 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
|
JP6853193B2
(ja)
*
|
2016-01-29 |
2021-03-31 |
協和キリン株式会社 |
核酸複合体
|
|
US10478503B2
(en)
|
2016-01-31 |
2019-11-19 |
University Of Massachusetts |
Branched oligonucleotides
|
|
US10246709B2
(en)
|
2016-03-07 |
2019-04-02 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
|
TWI794662B
(zh)
|
2016-03-14 |
2023-03-01 |
瑞士商赫孚孟拉羅股份公司 |
用於降低pd-l1表現之寡核苷酸
|
|
EP3429690A4
(en)
|
2016-03-16 |
2019-10-23 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR MODULATING KEAP1
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
EP3228326A1
(en)
*
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
|
KR102369898B1
(ko)
*
|
2016-04-08 |
2022-03-03 |
트랜슬레이트 바이오 인코포레이티드 |
다량체 코딩 핵산 및 그 용도
|
|
EP3442983A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
|
|
KR102706686B1
(ko)
|
2016-05-06 |
2024-09-19 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도
|
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
AU2017285350A1
(en)
|
2016-06-17 |
2018-12-20 |
F. Hoffmann-La Roche Ag |
Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
|
|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
EP3478839A1
(en)
|
2016-07-01 |
2019-05-08 |
H. Hoffnabb-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
US11753638B2
(en)
|
2016-08-12 |
2023-09-12 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
CA3035293A1
(en)
|
2016-09-01 |
2018-03-08 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded rna-editing oligonucleotides
|
|
JP6989521B2
(ja)
|
2016-09-02 |
2022-01-05 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
標的化リガンド
|
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
|
EP3568480A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
WO2018130585A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
WO2018130583A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
US20190338286A1
(en)
|
2017-01-13 |
2019-11-07 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
WO2018130581A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
EP3592365A4
(en)
*
|
2017-03-10 |
2021-01-13 |
The Board Of Regents Of The University Of Texas System |
TREATMENT FOR FOX ENDOTHAL CORNEAL DYSTROPHY
|
|
CN110536964A
(zh)
|
2017-03-10 |
2019-12-03 |
国立研究开发法人国立成育医疗研究中心 |
反义寡核苷酸和糖原贮积病Ia型预防或治疗用组合物
|
|
WO2018191278A2
(en)
*
|
2017-04-11 |
2018-10-18 |
Arbutus Biopharma Corporation |
Targeted compositions
|
|
WO2018215049A1
(en)
*
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
US11273222B2
(en)
|
2017-05-26 |
2022-03-15 |
National Cerebral And Cardiovascular Center |
Antisense nucleic acid targeting PCSK9
|
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
EP3630788A4
(en)
*
|
2017-06-02 |
2021-04-28 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
|
|
EP3599844A4
(en)
*
|
2017-06-07 |
2021-01-13 |
University of Massachusetts |
ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED PROCEDURES
|
|
CA3064590A1
(en)
|
2017-06-23 |
2018-12-27 |
University Of Massachusetts |
Two-tailed self-delivering sirna and related methods
|
|
WO2019030574A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding |
Cargomers
|
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
|
JP2020531450A
(ja)
|
2017-08-17 |
2020-11-05 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
調整性ｒｅｖｅｒｓｉｒ（商標）化合物
|
|
AU2018318231A1
(en)
|
2017-08-18 |
2020-02-13 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
|
US11596646B2
(en)
|
2017-10-12 |
2023-03-07 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
CN111226114A
(zh)
|
2017-10-13 |
2020-06-02 |
罗氏创新中心哥本哈根有限公司 |
用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
|
|
CN111511914B
(zh)
|
2017-10-16 |
2023-11-17 |
豪夫迈·罗氏有限公司 |
减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
|
|
WO2019090359A1
(en)
|
2017-11-06 |
2019-05-09 |
Nitto Denko Corporation |
Fusogenic compounds for delivery of biologically active molecules
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
JP7261494B2
(ja)
|
2017-12-01 |
2023-04-20 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
CN118236391A
(zh)
|
2017-12-01 |
2024-06-25 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105435A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN110997919B
(zh)
|
2017-12-01 |
2024-04-02 |
苏州瑞博生物技术股份有限公司 |
双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
|
|
US11660347B2
(en)
|
2017-12-01 |
2023-05-30 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
|
|
CN118638788A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
US20200385714A1
(en)
|
2017-12-11 |
2020-12-10 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
JP2021507253A
(ja)
|
2017-12-21 |
2021-02-22 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｈｔｒａ１ ｒｎａアンタゴニストについてのコンパニオン診断
|
|
TW201929870A
(zh)
|
2017-12-22 |
2019-08-01 |
丹麥商羅氏創新中心哥本哈根有限公司 |
包含二硫代磷酸酯核苷間連結之寡核苷酸
|
|
CA3084170A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
JP2021508327A
(ja)
|
2017-12-22 |
2021-03-04 |
ロシュ イノベーション センター コペンハーゲン エーエス |
新規のチオホスホラミダイト
|
|
CN110959011B
(zh)
*
|
2017-12-29 |
2023-03-28 |
苏州瑞博生物技术股份有限公司 |
缀合物及其制备方法和用途
|
|
WO2019137883A1
(en)
|
2018-01-10 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
|
MA51634A
(fr)
|
2018-01-12 |
2020-11-18 |
Roche Innovation Ct Copenhagen As |
Oligonucléotides antisens d'alpha-synucléine et leurs utilisations
|
|
US12241065B2
(en)
|
2018-01-12 |
2025-03-04 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
|
CN120310791A
(zh)
|
2018-01-12 |
2025-07-15 |
百时美施贵宝公司 |
靶向α-突触核蛋白的反义寡核苷酸及其用途
|
|
US20210095275A1
(en)
|
2018-01-12 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
|
US20200392510A1
(en)
|
2018-01-15 |
2020-12-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of dnm2 expression
|
|
EP3740574A1
(en)
|
2018-01-17 |
2020-11-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
|
WO2019141723A1
(en)
|
2018-01-18 |
2019-07-25 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting srebp1
|
|
KR20200116088A
(ko)
*
|
2018-01-26 |
2020-10-08 |
에프. 호프만-라 로슈 아게 |
방사성 표지된 올리고뉴클레오티드 및 이의 제조 방법
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
RU2020125769A
(ru)
*
|
2018-02-09 |
2022-03-10 |
Дженентек, Инк. |
Олигонуклеотиды для модуляции экспрессии tmem106b
|
|
CA3091789A1
(en)
|
2018-02-21 |
2019-08-29 |
Bristol-Myers Squibb Company |
Camk2d antisense oligonucleotides and uses thereof
|
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
EP3763815A4
(en)
|
2018-03-09 |
2021-12-15 |
Daiichi Sankyo Company, Limited |
THERAPEUTIC FOR GLYCOGEN STORAGE DISEASE OF TYPE IA
|
|
EP3768694A4
(en)
|
2018-03-22 |
2021-12-29 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
|
EP3775208A1
(en)
|
2018-04-05 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Use of fubp1 inhibitors for treating hepatitis b virus infection
|
|
CA3094020A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
|
JP2021522816A
(ja)
|
2018-05-07 |
2021-09-02 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチド治療のための超並列的探索方法
|
|
EP3790972A1
(en)
|
2018-05-08 |
2021-03-17 |
Regulus Therapeutics Inc. |
Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
|
|
WO2019215175A1
(en)
|
2018-05-08 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
SG11202010215TA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn3 expression
|
|
JP7438135B2
(ja)
|
2018-05-09 |
2024-02-26 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｆｘｉの発現を低下させるための化合物及び方法
|
|
SG11202010131QA
(en)
|
2018-05-11 |
2020-11-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
SG11202010841QA
(en)
*
|
2018-05-11 |
2020-11-27 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
CN112912500A
(zh)
|
2018-06-05 |
2021-06-04 |
豪夫迈·罗氏有限公司 |
用于调节atxn2表达的寡核苷酸
|
|
US11833168B2
(en)
|
2018-06-14 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
WO2020007892A1
(en)
|
2018-07-03 |
2020-01-09 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating tau expression
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
JP7616987B2
(ja)
|
2018-07-13 |
2025-01-17 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド
|
|
EP3823725A4
(en)
|
2018-07-17 |
2023-05-10 |
Aronora, Inc. |
METHODS FOR SAFELY REDUCING THROMBOPOIETIN
|
|
CA3106986A1
(en)
|
2018-07-25 |
2020-01-30 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn2 expression
|
|
JP7470097B2
(ja)
|
2018-07-31 |
2024-04-17 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロトリチオアートヌクレオシド間結合を含むオリゴヌクレオチド
|
|
KR20210041537A
(ko)
*
|
2018-07-31 |
2021-04-15 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포로트리티오에이트 뉴클레오사이드간 연결을 포함하는 올리고뉴클레오타이드
|
|
WO2020033899A1
(en)
|
2018-08-10 |
2020-02-13 |
University Of Massachusetts |
Modified oligonucleotides targeting snps
|
|
EP3842534A4
(en)
|
2018-08-21 |
2022-07-06 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
JP7627042B2
(ja)
|
2018-08-23 |
2025-02-05 |
ユニバーシティー オブ マサチューセッツ |
Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
|
|
WO2020038968A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
|
EP3844274A1
(en)
|
2018-08-28 |
2021-07-07 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
US20220056443A1
(en)
*
|
2018-09-06 |
2022-02-24 |
Aptamir Therapeutics, Inc. |
Metabolic benefits of short mir-22 mirna antagomir therapies
|
|
EP3862024A4
(en)
|
2018-09-30 |
2022-08-17 |
Suzhou Ribo Life Science Co., Ltd. |
SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
|
|
WO2020089260A1
(en)
|
2018-11-01 |
2020-05-07 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting tia1
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
EA202191342A1
(ru)
|
2018-11-15 |
2021-08-10 |
Айонис Фармасьютикалз, Инк. |
Модуляторы экспрессии irf5
|
|
US12281305B2
(en)
|
2018-11-21 |
2025-04-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing prion expression
|
|
WO2020117706A1
(en)
|
2018-12-03 |
2020-06-11 |
Triplet Therapeutics, Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
|
|
CN113631709A
(zh)
|
2018-12-20 |
2021-11-09 |
普拉克西斯精密药物股份有限公司 |
用于治疗kcnt1相关病症的组合物和方法
|
|
EP3898975A2
(en)
|
2018-12-21 |
2021-10-27 |
Boehringer Ingelheim International GmbH |
Antisense oligonucleotides targeting card9
|
|
CN112423794A
(zh)
|
2018-12-28 |
2021-02-26 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2020150636A1
(en)
|
2019-01-18 |
2020-07-23 |
University Of Massachusetts |
Dynamic pharmacokinetic-modifying anchors
|
|
EP3914232A1
(en)
*
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipid vesicle for oral drug delivery
|
|
MX2021008918A
(es)
|
2019-01-31 |
2021-08-24 |
Ionis Pharmaceuticals Inc |
Moduladores de expresion yap1.
|
|
CA3129646A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
CA3130431A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Phosphonoacetate gapmer oligonucleotides
|
|
JP7503072B2
(ja)
|
2019-02-26 |
2024-06-19 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドの製剤化方法
|
|
WO2020176771A1
(en)
|
2019-02-27 |
2020-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of malat1 expression
|
|
EP3934695A1
(en)
*
|
2019-03-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Intracellular targeting of molecules
|
|
CA3135180A1
(en)
|
2019-03-29 |
2020-10-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating ube3a-ats
|
|
CA3132178A1
(en)
|
2019-04-02 |
2020-10-08 |
Aliye Seda Yilmaz-Elis |
Antisense oligonucleotides for immunotherapy
|
|
WO2020206115A2
(en)
|
2019-04-03 |
2020-10-08 |
Bristol-Myers Squibb Company |
Angptl2 antisense oligonucleotides and uses thereof
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
EP3947677A1
(en)
|
2019-04-04 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating atxn2 expression
|
|
JP7663951B2
(ja)
|
2019-05-22 |
2025-04-17 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
AU2020280439B2
(en)
|
2019-05-22 |
2025-08-14 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
CN113811613B
(zh)
|
2019-05-22 |
2024-04-05 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
WO2020238766A1
(zh)
|
2019-05-24 |
2020-12-03 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
EP3976056A2
(en)
|
2019-05-31 |
2022-04-06 |
Aligos Therapeutics, Inc. |
Modified gapmer oligonucleotides and methods of use
|
|
CN113950529A
(zh)
|
2019-06-06 |
2022-01-18 |
豪夫迈·罗氏有限公司 |
靶向atxn3的反义寡核苷酸
|
|
ES3048358T3
(en)
|
2019-07-26 |
2025-12-10 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating gfap
|
|
US20230114023A1
(en)
*
|
2019-07-30 |
2023-04-13 |
Mpeg La, L.L.C. |
Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
|
|
CA3149835A1
(en)
|
2019-08-09 |
2021-02-18 |
University Of Massachusetts |
Chemically modified oligonucleotides targeting snps
|
|
WO2021049504A1
(ja)
|
2019-09-10 |
2021-03-18 |
第一三共株式会社 |
肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
KR20220110729A
(ko)
*
|
2019-10-02 |
2022-08-09 |
서나오믹스, 인크. |
뉴클레오시드 유사체를 포함하는 올리고뉴클레오티드
|
|
WO2021122735A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of sept9 inhibitors for treating hepatitis b virus infection
|
|
WO2021122869A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of scamp3 inhibitors for treating hepatitis b virus infection
|
|
EP4077671A1
(en)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Use of saraf inhibitors for treating hepatitis b virus infection
|
|
WO2021122921A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of cops3 inhibitors for treating hepatitis b virus infection
|
|
EP4706689A2
(en)
*
|
2019-12-19 |
2026-03-11 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
CN114829601A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
TW202136510A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制ｓｃｎ９ａ表現之增強型寡核苷酸
|
|
AU2020410993A1
(en)
|
2019-12-24 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
CN114828852A
(zh)
|
2019-12-24 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
|
|
WO2021152005A1
(en)
|
2020-01-28 |
2021-08-05 |
Universite De Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
|
CN115176010A
(zh)
|
2020-02-28 |
2022-10-11 |
豪夫迈·罗氏有限公司 |
用于调节cd73外显子7剪接的寡核苷酸
|
|
PH12022552258A1
(en)
|
2020-02-28 |
2023-11-20 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating smn2
|
|
GB2627644B
(en)
|
2020-03-04 |
2024-11-20 |
Verve Therapeutics Inc |
Method for the preparation of GalNAc-lipid nanoparticle
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
CA3176196A1
(en)
*
|
2020-04-21 |
2021-10-28 |
Flagship Pioneering, Inc. |
Bifunctional molecules and methods of using thereof
|
|
KR20230005933A
(ko)
|
2020-05-01 |
2023-01-10 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Atxn1을 조정하는 화합물 및 방법
|
|
WO2021231204A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
|
CN115551519A
(zh)
|
2020-05-11 |
2022-12-30 |
基因泰克公司 |
用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
|
|
EP4150085A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
TW202208628A
(zh)
|
2020-05-13 |
2022-03-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向顆粒蛋白前體之寡核苷酸促效劑
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
EP4150077A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
WO2021233551A1
(en)
|
2020-05-22 |
2021-11-25 |
F.Hoffmann-La Roche Ag |
Oligonucleotides for splice modulation of card9
|
|
EP4157289A4
(en)
|
2020-05-26 |
2024-06-26 |
University Of Massachusetts |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
|
US20230212572A1
(en)
|
2020-06-09 |
2023-07-06 |
Roche Innovation Center Copenhagen A/S |
Guanosine Analogues for Use in Therapeutics Polynucleotides
|
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
|
IL298530A
(en)
|
2020-06-29 |
2023-01-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating plp1
|
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
|
WO2022018187A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting rna binding protein sites
|
|
KR20230043914A
(ko)
|
2020-07-28 |
2023-03-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
App 발현을 감소시키기 위한 화합물 및 방법
|
|
CN111671913B
(zh)
*
|
2020-07-30 |
2022-02-08 |
四川大学 |
一种量子点-小核酸偶联物及其用途
|
|
TW202221123A
(zh)
|
2020-08-07 |
2022-06-01 |
美商Ionis製藥公司 |
調節ｓｃｎ２ａ之化合物及方法
|
|
EP4200419A2
(en)
|
2020-08-21 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Use of a1cf inhibitors for treating hepatitis b virus infection
|
|
CA3194161A1
(en)
*
|
2020-10-02 |
2022-04-07 |
David M. Evans |
Nucleoside containing sirnas for treating viral diseases
|
|
JP7820374B2
(ja)
|
2020-11-18 |
2026-02-25 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
アンジオテンシノーゲン発現を調節するための化合物及び方法
|
|
WO2022117747A2
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
AR124229A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
|
US12018261B2
(en)
|
2020-12-18 |
2024-06-25 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating factor XII
|
|
JP2023553710A
(ja)
|
2020-12-18 |
2023-12-25 |
エフ． ホフマン－ラ ロシュ アーゲー |
プログラニュリンを標的とするためのアンチセンスオリゴヌクレオチド
|
|
CN116670282A
(zh)
|
2020-12-22 |
2023-08-29 |
豪夫迈·罗氏有限公司 |
靶向xbp1的寡核苷酸
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
US20240083990A1
(en)
|
2021-01-26 |
2024-03-14 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
|
|
PE20240696A1
(es)
|
2021-03-08 |
2024-04-10 |
Servier Lab |
Oligonucleotidos antisentido para inhibir la expresion de la alfa-sinucleina
|
|
WO2022232650A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing agt expression
|
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
JP2024524874A
(ja)
|
2021-06-08 |
2024-07-09 |
エフ． ホフマン－ラ ロシュ アーゲー |
オリゴヌクレオチドプログラニュリンアゴニスト
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
EP4355759A4
(en)
|
2021-06-18 |
2026-05-13 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF IFNAR1
|
|
AR126207A1
(es)
|
2021-06-23 |
2023-09-27 |
Univ Massachusetts |
Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogénicos
|
|
US20250034564A1
(en)
|
2021-06-29 |
2025-01-30 |
Korro Bio, Inc. |
Methods and Compositions for ADAR-Mediated Editing
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
EP4380576A4
(en)
|
2021-08-03 |
2026-04-29 |
Verve Therapeutics Inc |
RNA TARGETED COMPOSITIONS AND ADMINISTRATION METHODS
|
|
WO2023034561A2
(en)
*
|
2021-09-02 |
2023-03-09 |
Vanderbilt University |
Lipophilic oligonucleotide conjugates
|
|
MX2024003266A
(es)
|
2021-09-16 |
2024-04-03 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
|
|
AU2022370009A1
(en)
|
2021-10-22 |
2024-05-16 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
|
IL312635A
(en)
|
2021-11-11 |
2024-07-01 |
Hoffmann La Roche |
Pharmaceutical combinations for treatment of hbv
|
|
JP2025501682A
(ja)
*
|
2021-12-03 |
2025-01-23 |
クラリス コーポレーション |
改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド
|
|
CN118434858A
(zh)
|
2021-12-07 |
2024-08-02 |
豪夫迈·罗氏有限公司 |
靶向actl6b的反义寡核苷酸
|
|
JP2024546887A
(ja)
|
2021-12-17 |
2024-12-26 |
ジェネンテック， インコーポレイテッド |
オリゴヌクレオチドｇｂａアゴニスト
|
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
|
EP4453206A1
(en)
|
2021-12-20 |
2024-10-30 |
F. Hoffmann-La Roche AG |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
|
US20240167040A1
(en)
|
2022-02-21 |
2024-05-23 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotide
|
|
US20250188478A1
(en)
|
2022-03-16 |
2025-06-12 |
Daiichi Sankyo Company, Limited |
siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2
|
|
JPWO2023176863A1
(enExample)
|
2022-03-16 |
2023-09-21 |
|
|
|
CN119173632A
(zh)
|
2022-05-10 |
2024-12-20 |
豪夫迈·罗氏有限公司 |
靶向cfp-elk1基因间区域的反义寡核苷酸
|
|
KR20250011958A
(ko)
|
2022-05-18 |
2025-01-22 |
에프. 호프만-라 로슈 아게 |
Rna 결합 단백질 부위를 표적으로 하는 개선된 올리고뉴클레오티드
|
|
EP4282964A1
(en)
*
|
2022-05-23 |
2023-11-29 |
Universitat de Valéncia |
Oligonucleotides conjugated to oleic acid and uses thereof
|
|
CN119365600A
(zh)
|
2022-06-17 |
2025-01-24 |
豪夫迈·罗氏有限公司 |
靶向颗粒蛋白前体的反义寡核苷酸
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
IL318655A
(en)
|
2022-09-06 |
2025-03-01 |
Hoffmann La Roche |
Double RNA molecule for ocular administration
|
|
CN120239607A
(zh)
|
2022-09-23 |
2025-07-01 |
Ionis制药公司 |
用于降低mecp2表达的化合物和方法
|
|
WO2024112809A2
(en)
*
|
2022-11-21 |
2024-05-30 |
Pepgen Inc. |
Cell-penetrating peptides, conjugates thereof, and methods of their use
|
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
EP4652273A1
(en)
|
2023-01-16 |
2025-11-26 |
Institut National de la Recherche pour l'Agriculture, l'Alimentation et l'Environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
CN120936707A
(zh)
|
2023-01-19 |
2025-11-11 |
奥托斯实验室公司 |
再生因子在器官移植中的用途
|
|
WO2024196893A1
(en)
*
|
2023-03-17 |
2024-09-26 |
Camford Labs Inc. |
Chemically modified nucleotides
|
|
JP2026514403A
(ja)
*
|
2023-03-30 |
2026-05-11 |
ラクティゲン セラピューティクス |
オリゴヌクレオチド送達担体およびその使用方法
|
|
UY40699A
(es)
|
2023-04-05 |
2024-08-30 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de pln
|
|
WO2024227765A2
(en)
|
2023-05-04 |
2024-11-07 |
F. Hoffmann-La Roche Ag |
Oligonucleotides capable of upregulating glucocerebrosidase expression
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
KR20260026070A
(ko)
|
2023-06-16 |
2026-02-25 |
에프. 호프만-라 로슈 아게 |
Jak1 발현 조절을 위한 이중 가닥 올리고뉴클레오티드
|
|
KR20260052996A
(ko)
|
2023-08-16 |
2026-04-20 |
르 라보레또레 쎄르비에르 |
Kcnt1 발현을 조정하기 위한 올리고뉴클레오티드
|
|
IL327100A
(en)
|
2023-09-15 |
2026-05-01 |
Praxis Prec Medicines Inc |
Alsonarsen/PRAX-22 for use in the treatment of SCN2A-related disorders
|
|
WO2026006436A1
(en)
|
2024-06-25 |
2026-01-02 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
|
|
WO2026024954A2
(en)
|
2024-07-24 |
2026-01-29 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
EP4711455A1
(en)
|
2024-09-11 |
2026-03-18 |
Aarhus Universitet |
Small artificial rna (smartrna) oligonucleotide for modulating protein expression
|